TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate (Q35256427)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

7 August 2017

TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate (English)

1 reference

Europe PubMed Central

7 August 2017

0 references

abiraterone acetate

1 reference

ChEBI release 2020-05-28

prostate cancer

1 reference

based on heuristic

inferred from title

object named as

Hans Lilja

7

0 references

author name string

Daniel C Danila

1

1 reference

Europe PubMed Central

7 August 2017

Aseem Anand

2

1 reference

Europe PubMed Central

7 August 2017

Clifford C Sung

3

1 reference

Europe PubMed Central

7 August 2017

Glenn Heller

4

1 reference

Europe PubMed Central

7 August 2017

Margaret A Leversha

5

1 reference

Europe PubMed Central

7 August 2017

Long Cao

6

1 reference

Europe PubMed Central

7 August 2017

Arturo Molina

8

1 reference

Europe PubMed Central

7 August 2017

Charles L Sawyers

9

1 reference

Europe PubMed Central

7 August 2017

Martin Fleisher

10

1 reference

Europe PubMed Central

7 August 2017

Howard I Scher

11

1 reference

Europe PubMed Central

7 August 2017

language of work or name

0 references

publication date

14 July 2011

1 reference

Europe PubMed Central

7 August 2017

European Urology

1 reference

Europe PubMed Central

7 August 2017

60

1 reference

Europe PubMed Central

7 August 2017

5

1 reference

Europe PubMed Central

7 August 2017

897-904

1 reference

Europe PubMed Central

7 August 2017

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185163

12 July 2018

The genomic complexity of primary human prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185163

12 July 2018

Integrative genomic profiling of human prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185163

12 July 2018

TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185163

12 July 2018

An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185163

12 July 2018

Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185163

12 July 2018

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185163

12 July 2018

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185163

12 July 2018

Studies of TMPRSS2-ERG gene fusions in diagnostic trans-rectal prostate biopsies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185163

12 July 2018

ETS gene fusions in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185163

12 July 2018

Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185163

12 July 2018

Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185163

12 July 2018

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185163

12 July 2018

ETS rearrangements and prostate cancer initiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185163

12 July 2018

Detection of mutations in EGFR in circulating lung-cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185163

12 July 2018

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185163

12 July 2018

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185163

12 July 2018

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185163

12 July 2018

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185163

12 July 2018

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185163

12 July 2018

Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185163

12 July 2018

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185163

12 July 2018

TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185163

26 September 2018

Tumour-associated transcripts and EGFR deletion variants in colorectal cancer in primary tumour, metastases and circulating tumour cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185163

26 September 2018

The Biomarkers Consortium: on the critical path of drug discovery.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185163

26 September 2018

A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185163

26 September 2018

Reporting recommendations for tumor marker prognostic studies (REMARK).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3185163

26 September 2018

Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21802835

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21802835

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.EURURO.2011.07.011

1 reference

Europe PubMed Central

7 August 2017

1 reference

Europe PubMed Central

7 August 2017

1 reference

Europe PubMed Central

7 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35256427&oldid=1602542301"